Ceapro Inc (CZO.CA) Stock Price, Quote, News and Overview
TSX-V:CZO - TSX Venture Exchange - CA1499071076 - Common Stock - Currency: CAD
CZO.CA Quote, Performance and Key Statistics
TSX-V:CZO (5/31/2024, 7:00:00 PM)
0.225
-0.03 (-11.76%)
The current stock price of CZO.CA is 0.225 CAD. In the past month the price decreased by -6.25%. In the past year, price decreased by -51.09%.
CZO.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| AIM-PR-C.CA | AIMIA INC - AIMCN 7.773 PERP | N/A | 1.92B | ||
| AIM-PR-A.CA | AIMIA INC - AIMCN 4.802 PERP | N/A | 1.83B | ||
| VNP.CA | 5N PLUS INC | 29.29 | 1.33B | ||
| NEO.CA | NEO PERFORMANCE MATERIALS IN | N/A | 705.50M | ||
| AIM.CA | AIMIA INC | N/A | 291.70M | ||
| ECO.CA | ECOSYNTHETIX INC | N/A | 240.16M | ||
| BPYP-PR-A.CA | Brookfield Property Preferred LP | N/A | 166.70M | ||
| NANO.CA | NANO ONE MATERIALS CORP | N/A | 107.04M | ||
| HPQ.CA | HPQ SILICON INC | N/A | 65.40M | ||
| BU.CA | BURCON NUTRASCIENCE CORP | N/A | 34.64M | ||
| AUUA.CA | ALUULA COMPOSITES INC | N/A | 32.58M |
Related stock screener links
About CZO.CA
Company Profile
Ceapro, Inc. is a Canadian biotechnology company, which engages in the development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. The company is headquartered in Edmonton, Alberta. The firm is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The firm's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.
Company Info
Ceapro Inc
7824 51 Ave NW
Edmonton ALBERTA T6E 6W2 CA
CEO: Gilles Gagnon
Employees: 0
Phone: 17804214555
Ceapro Inc / CZO.CA FAQ
What is the stock price of Ceapro Inc today?
The current stock price of CZO.CA is 0.225 CAD. The price decreased by -11.76% in the last trading session.
What is the ticker symbol for Ceapro Inc stock?
The exchange symbol of Ceapro Inc is CZO and it is listed on the TSX Venture Exchange exchange.
On which exchange is CZO.CA stock listed?
CZO.CA stock is listed on the TSX Venture Exchange exchange.
What is the price forecast or stock price prediction for Ceapro Inc stock?
9 analysts have analysed CZO.CA and the average price target is 1.1 CAD. This implies a price increase of 389.6% is expected in the next year compared to the current price of 0.225. Check the Ceapro Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Ceapro Inc worth?
Ceapro Inc (CZO.CA) has a market capitalization of 17.62M CAD. This makes CZO.CA a Nano Cap stock.
How many employees does Ceapro Inc have?
Ceapro Inc (CZO.CA) currently has 0 employees.
What are the support and resistance levels for Ceapro Inc (CZO.CA) stock?
Ceapro Inc (CZO.CA) has a support level at 0.21 and a resistance level at 0.28. Check the full technical report for a detailed analysis of CZO.CA support and resistance levels.
Should I buy Ceapro Inc (CZO.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CZO.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CZO.CA, evaluating the profitability, health, valuation and growth aspects
- Ceapro Inc (CZO.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Ceapro Inc (CZO.CA) Sales and EPS estimates to see what analysts future expectations are.
- Ceapro Inc (CZO.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Ceapro Inc (CZO.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- Ceapro Inc (CZO.CA) Stock Chart to make your own analysis
- Ceapro Inc (CZO.CA) Latest news and press-releases to stay up to date.
Does Ceapro Inc (CZO.CA) stock pay dividends?
CZO.CA does not pay a dividend.
When does Ceapro Inc (CZO.CA) report earnings?
Ceapro Inc (CZO.CA) will report earnings on 2024-08-27, before the market open.
What is the Price/Earnings (PE) ratio of Ceapro Inc (CZO.CA)?
Ceapro Inc (CZO.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.06).
CZO.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CZO.CA. When comparing the yearly performance of all stocks, CZO.CA is a bad performer in the overall market: 87.91% of all stocks are doing better.
CZO.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CZO.CA. CZO.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
CZO.CA Financial Highlights
Over the last trailing twelve months CZO.CA reported a non-GAAP Earnings per Share(EPS) of -0.06. The EPS decreased by -206.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.98% | ||
| ROE | -16.91% | ||
| Debt/Equity | 0.07 |
CZO.CA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to CZO.CA. The Buy consensus is the average rating of analysts ratings from 9 analysts.